[CDTX] Cidara Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11 Change: 0.8 (7.84%)

chart CDTX

Refresh chart

Strongest Trends Summary For CDTX

CDTX is in the medium-term down -18% below S&P in 2 months and down -49% below S&P in 1 year. In the long-term down -64% below S&P in 2 years and down -86% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities41.41 M Cash From Investing Activities-30 K Cash From Operating Activities-6.05 M Gross Profit
Net Profit-6.74 M Operating Profit-6.73 M Total Assets60.78 M Total Current Assets58.4 M
Total Current Liabilities3.81 M Total Debt Total Liabilities3.84 M Total Revenue
Technical Data
High 52 week8.15 Low 52 week2.1 Last close2.7 Last change-1.82%
RSI43.04 Average true range0.21 Beta0.77 Volume27 K
Simple moving average 20 days-0.41% Simple moving average 50 days-1.22% Simple moving average 200 days-32.44%
Performance Data
Performance Week6.72% Performance Month-7.22% Performance Quart-24.16% Performance Half-40.66%
Performance Year-57.81% Performance Year-to-date14.89% Volatility daily2.24% Volatility weekly5%
Volatility monthly10.25% Volatility yearly35.5% Relative Volume259.89% Average Volume118.6 K
New High New Low

News

2019-03-07 08:00:00 | Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting

2019-03-04 12:19:18 | Have Insiders Been Buying Cidara Therapeutics, Inc. NASDAQ:CDTX Shares?

2019-02-28 16:24:36 | Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-05 08:00:00 | Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy TCT Meeting

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2018-12-21 09:54:04 | How Does Investing In Cidara Therapeutics, Inc. NASDAQ:CDTX Impact The Volatility Of Your Portfolio?

2018-12-03 08:00:00 | Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary

2018-11-27 08:38:01 | Cidara Therapeutics CDTX Enters Oversold Territory

2018-11-27 08:00:00 | Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients

2018-11-14 08:30:00 | New Research Coverage Highlights Alcentra Capital, VeriSign, Americold Realty Trust, Internet Initiative Japan, DAVIDsTEA, and Cidara Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-12 08:00:00 | Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

2018-11-08 17:38:29 | Cidara Therapeutics: 3Q Earnings Snapshot

2018-11-08 17:23:17 | Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results

2018-10-24 08:00:00 | Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress

2018-10-15 08:00:00 | Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference

2018-10-04 08:00:00 | Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018

2018-09-27 08:00:00 | Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections

2018-09-25 13:16:57 | Shareholders Should Check If Insiders Own Shares In Cidara Therapeutics Inc NASDAQ:CDTX

2018-09-25 08:00:00 | FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program

2018-09-24 16:05:00 | Cidara Therapeutics to Present at Two Upcoming Investor Conferences

2018-09-12 16:02:00 | Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors

2018-09-12 08:00:00 | Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018

2018-09-04 08:00:00 | Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting

2018-08-08 16:54:26 | Cidara Therapeutics: 2Q Earnings Snapshot

2018-08-08 16:30:00 | Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results

2018-07-30 08:00:12 | Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy?

2018-06-15 08:00:00 | Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences

2018-06-06 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

2018-05-23 08:00:00 | Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections

2018-05-21 08:15:00 | Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections

2018-05-21 07:30:00 | Cidara Therapeutics Announces Offering of Common Stock and Warrants

2018-05-11 05:12:21 | Cidara Therapeutics: 1Q Earnings Snapshot

2018-05-10 16:05:00 | Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

2018-04-20 10:17:00 | Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2018-04-04 08:00:00 | Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting

2018-03-21 08:00:00 | Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin

2018-03-21 07:40:00 | Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin

2018-03-19 08:50:12 | Options Traders Expect Huge Moves in Cidara Therapeutics CDTX Stock

2018-03-19 07:42:06 | Cidara Therapeutics' stock soars toward 13-month high after positive drug trial results

2018-03-19 07:30:00 | Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

2018-03-08 08:00:00 | Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting

2018-03-01 16:05:00 | Cidara Announces Appointment of Chrysa Mineo as Independent Director

2018-02-28 05:03:14 | Cidara Therapeutics reports 4Q loss

2018-02-27 16:32:00 | Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

2018-01-30 10:18:00 | The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair

2018-01-29 08:00:00 | Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting

2018-01-08 15:20:58 | 2018 Could Be Hallmark Year For These Two Antifungal Companies

2018-01-04 08:00:00 | Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections

2017-11-28 08:30:00 | Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin CD101 IV in Invasive Fungal Infections

2017-11-13 08:30:00 | Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace